Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

COPENHAGEN, Denmark — Novo Nordisk sued Hims and Hers Health on Monday over alleged patent infringement after the U.S. telehealth firm launched, then canceled, a $49 copy of Novo's weight-loss pill ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knockoffs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...

Hims & Hers (HIMS) on Monday called a patent lawsuit filed by Novo Nordisk (NVO) over IP rights linked to the Danish drugmaker’s weight loss therapy, semaglutide, “a blatant attack” targeting ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

To get the bad news out of the way, Novo Nordisk provided pretty dismal guidance for 2026 when it reported 2025 earnings. There are obviously a lot of moving parts, but the big picture numbers are ...

The manufacturer of two GLP-1 weight-loss drugs, Ozempic and Wegovy, is up in arms over the recent introduction of a $49 alternative pill by the telehealth company Hims & Hers. Denmark’s Novo Nordisk ...

Novo Nordisk shares rallied on Friday in what’s still been a painful week as the Food and Drug Administration may weigh in on the side of the Danish drugmaker in its dispute over a copycat drug. Novo ...

Not even two days after Novo Nordisk A/S pinned its comeback hopes on a new weight-loss pill that’s off to a strong start, a knock-off version is already on the market that the Danish drugmaker says ...

The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, which gave a much rosier outlook to investors. By Eshe Nelson Novo Nordisk, ...